Pregnane X Receptor Expression in Human Pancreatic Adenocarcinoma: Associations With Clinicopathologic Parameters, Tumor Proliferative Capacity, Patients' Survival, and Retinoid X Receptor Expression
| Autor: | Adamantia Zizi-Serbetzoglou, Ioannis Koutsounas, Gregorios Kouraklis, Constantinos Giaginis, Stamatios Theocharis, Efstratios Patsouris, Paraskevi Alexandrou |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male medicine.medical_specialty Receptors Steroid Endocrinology Diabetes and Metabolism Kaplan-Meier Estimate Steroid biosynthesis Retinoid X receptor Biology Adenocarcinoma Malignancy medicine.disease_cause digestive system Endocrinology Internal medicine Internal Medicine medicine Humans Retinoid X Receptor gamma Receptor Lymph node Aged Neoplasm Staging Proportional Hazards Models Retinoid X Receptor beta Aged 80 and over Pregnane X receptor Chi-Square Distribution Retinoid X Receptor alpha Hepatology Pregnane X Receptor Middle Aged medicine.disease Immunohistochemistry digestive system diseases Pancreatic Neoplasms medicine.anatomical_structure Retinoid X Receptors Multivariate Analysis Disease Progression Female Carcinogenesis |
| Zdroj: | Pancreas. 44(7) |
| ISSN: | 1536-4828 |
| Popis: | Objectives Pregnane X receptor (PXR) has been involved in human malignancy, either by directly affecting carcinogenesis or by inducing drug-drug interactions and chemotherapy resistance. The present study aimed to assess the clinical significance of PXR in pancreatic adenocarcinoma. Methods Pregnane X receptor and its heterodimers' PXR/retinoid X receptor α (RXR-α), RXR-β, and RXR-γ expression were assessed immunohistochemically on tumoral samples from 55 pancreatic adenocarcinoma patients and were associated with clinicopathologic parameters, tumor proliferative capacity, and patients' survival. Results Enhanced PXR expression was noted in 24 (43.6%) of 55 pancreatic adenocarcinoma cases. Pancreatic adenocarcinoma patients presenting increased histological grade of tumor differentiation showed a significant increased incidence of elevated PXR expression (P = 0.023). Enhanced PXR/RXR-β expression was significantly associated with smaller tumor size and earlier clinical stage (P = 0.005 and P = 0.003, respectively). Elevated PXR/RXR-γ expression was significantly associated with smaller tumor size and earlier clinical stage (P = 0.012 and P = 0.014, respectively) and borderline with the absence of lymph node metastases (P = 0.056). In addition, pancreatic adenocarcinoma patients presenting enhanced PXR/RXR-γ expression showed marginally longer survival times compared with those with decreased expression (log-rank test, P = 0.053). Conclusions This study supported evidence that PXR and its copartners' overexpression may be associated with favorable clinicopathologic parameters and better outcome in pancreatic adenocarcinoma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|